https://vitasmlab.net

NOROMARK

Norovirus Targeted Library

Human noroviruses are a leading cause of acute gastroenteritis worldwide, affecting millions annually across all age groups. They spread rapidly through contaminated food, surfaces, and person-to-person contact, causing severe vomiting and diarrhea that can lead to dehydration, particularly in the young and elderly. Outbreaks in healthcare facilities, cruise ships, and military settings disrupt essential services and impose a substantial economic burden. The virus's high genetic diversity and capacity for rapid evolution allow it to evade population immunity, complicating vaccine development. There are current- ly no approved antivirals or specific treatments for norovirus infection, making the development of new small molecule drugs a critical priority. Such agents could target viral proteases or polymerases, offering effective post-exposure prophylaxis and reducing transmission during outbreaks. Novel antivirals could also limit symptom severity and duration, providing essential tools to manage this resilient and widespread pathogen, especially among vulnerable populations.





STK822945



STL084597



STL429612

Norovirus Targeted Library (NOROMARK) consists of compounds with potential antiviral activity, which were selected based on similarity to known potential effectors of noroviral proteins. This library was designed to provide a potential starting point or to expand ongoing drug discovery project. It is designed in a way that maximizes structural diversity and excludes problematic compounds. This library has 1872 compounds. All compounds follow RO5.

Distribution of Parameters



If you have any specific needs for your project, we can provide specially tailored compound library based on your request.

Have questions or need a quote? Contact Irina Haywood (Ryabushenko) at

irina@vitasmlab.biz

Let's Connect on LinkedIn! Expand your professional network.

We look forward to collaborating with you!

Empowering Your Research, One Molecule at a Time.